 |
Prospector
Profile
07.1218
|
| |
| Anadys Pharmaceuticals, Inc. |
NAICS |
541710 |
| 3115 Merryfield Row
San Diego, CA 92121 |
Description |
Biotechnology |
| (858) 530-3600 |
Employees |
86 |
| http://www.anadyspharma.com/ |
Revenue |
(mil) |
0.0050 |
| |
Income |
(mil) |
-26.7600 |
| |
Assets |
(mil) |
89.4010 |
| |
Liability |
(mil) |
28.1450 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Anadys Pharmaceuticals, Inc. reported a net loss of $6,996,000 for the three months ended June 30, 2007, slightly lower than the net loss reported during the same quarter last year of $7,078,000. For the six months ended June 30, 2007, the Company has a net loss of $13,679,000, which is higher than the $12,883,000 net loss during the same period a year ago. As a result of its recurring losses, the Company has an accumulated deficit of $228,159,000 as of June 30, 2007.
|
| |
|
Intellectual Property:
As of December 31, 2006, the Company has 18 issued U.S. patents, 40 foreign patents and over 260 pending patent applications worldwide. Of these, 1 issued U.S. patent, 2 pending U.S. patent applications and approximately 135 pending foreign patent applications relate to ANA975. In addition, 2 of the U.S. patents and approximately 25 of the foreign patents relate to isatoribine and expire in 2007 or 2008. The Company obtained rights to the isatoribine patents through an agreement with Valeant Pharmaceuticals International. The patents and patent applications include coverage of its drug discovery technologies, composition of matter claims as well as method of use claims. [SEC Filing 10-K 03-15-07]
|
| |
|
Description:
The Company engages in discovery, development, and commercialization of small molecule medicines for the treatment of viral diseases and cancer.
|
| |
|
Officers:
Lawrence C. Fritz, Ph.D. (Pres., CEO & Dir.); James T. Glover (SVP & CFO); Devron R. Averett, Ph.D. (Chief Scientific Officer); James L. Freddo, M.D. (Chief Medical Officer); Mary Yaroshevsky-Glanville (VP); Carol G. Gallagher, Pharm.D. (VP); Elizabeth E. Reed, J.D. (VP & Sec.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol ANDS; NasdaqGM;
28,651,106 common shares outstanding as of August 1, 2007.
|
| |
| |
| |
| return to main page |
|
|
